Biocryst Pharmaceuticals (BCRX) Return on Capital Employed (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) posted Return on Capital Employed of 129.78% for Q1 2026, down 208.18% on a QoQ basis from 119.97% in Q4 2025, and down 13939.0% year-over-year from N/an in Q1 2025.
Biocryst Pharmaceuticals (BCRX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 129.78% for Q1 2026.
- Quarterly Return on Capital Employed fell 13939.0% year-over-year to 129.78% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 129.78% (down 13939.0% YoY) and the FY2025 annual result came in at 111.35%, up 11209.0% from the prior year.
- Return on Capital Employed was 129.78% for Q1 2026 at Biocryst Pharmaceuticals, down from 119.97% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 119.97% in Q4 2025 and bottomed at 129.78% in Q1 2026.
- A 5-year average of 15.42% and a median of 24.64% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed surged 12074 bps — and 2026, when it sank 13939 bps.
- Biocryst Pharmaceuticals' Return on Capital Employed stood at 33.08% in 2022, then rose by 15 bps to 28.03% in 2023, then soared by 97 bps to 0.77% in 2024, then surged by 15690 bps to 119.97% in 2025, then tumbled by 208 bps to 129.78% in 2026.
- Business Quant data shows BCRX's Return on Capital Employed at 129.78% in Q1 2026, 119.97% in Q4 2025, and 29.09% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | -129.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -129.78% |
| Dec 31, 2025 | 119.97% |
| Sep 30, 2025 | 29.09% |
| Jun 30, 2025 | 18.60% |
| Mar 31, 2025 | 9.60% |
| Dec 31, 2024 | -0.77% |
| Sep 30, 2024 | -12.40% |
| Jun 30, 2024 | -17.68% |
| Mar 31, 2024 | -24.10% |
| Dec 31, 2023 | -28.03% |
| Sep 30, 2023 | -24.64% |
| Jun 30, 2023 | -26.48% |
| Mar 31, 2023 | -28.53% |
| Dec 31, 2022 | -33.08% |
| Sep 30, 2022 | -34.07% |
| Jun 30, 2022 | -42.82% |
| Mar 31, 2022 | -36.97% |
| Dec 31, 2021 | -54.98% |
| Sep 30, 2021 | -129.03% |
| Jun 30, 2021 | -106.64% |